Wall Street Trims Ratings for Novo Nordisk Stock, as Ozempic's Competition Grows -- Barrons.com
10 Health Care Stocks Whale Activity In Today's Session
Eli Lilly Vows to Make Weight-Loss Pill in U.S. as Trump Pushes for Domestic Manufacturing -- Barrons.com
Daily short sale tracking: Petroleo Brasileiro SA Petrobras's short volume increased by 3 million, with a short sale ratio of 21%
Today's Analyst Rating | Evercore Upgrades Apple to Buy, Morgan Stanley Cuts Its Price Target Cut on Alphabet-C to $185
TD Cowen Maintains Novo-Nordisk A/S(NVO.US) With Buy Rating, Maintains Target Price $105
Guggenheim Downgrades Novo-Nordisk A/S(NVO.US) to Hold Rating
Netflix, UnitedHealth, Novo Nordisk, Tesla And Trump Media: Why These 5 Stocks Are On Investors' Radars Today
Top Gap Ups and Downs on Thursday: LLY, UNH, NVO and More
Novo-Nordisk A/S Options Spot-On: On April 17th, 84,735 Contracts Were Traded, With 524.74K Open Interest
SA Asks: What's the Best Weight-loss Drug Stock Right Now?
Novo Nordisk May Lag Behind Eli Lilly In Cardiometabolic Race, Analyst Downgrades Stock
Why Did Lilly Data for Oral Obesity Drug Boost Structure and Metsera?
Trending Stocks Today | Adagio Medical Soars 92.77%
Novo Nordisk's ADRs Slide After Eli Lilly Obesity Pill Results -- Market Talk
European Equities Traded in the US as American Depositary Receipts Modestly Higher in Thursday Trading
Express News | Eli Lilly Stock Soars, Boosted by Weight-Loss Pill Trial Results; Rival Novo Nordisk Slumps
Eli Lilly and Co soared over 13%! The Phase III clinical data for the oral weight-loss drug Orforglipron is impressive, surpassing the effects of Novo-Nordisk A/S Ozempic.
Patients taking Eli Lilly and Co's Orforglipron lost an average of 16 pounds, equivalent to 7.9% of their body weight. In contrast, Novo-Nordisk A/S's flagship product Ozempic only led to a weight loss of about 6% for diabetes patients at the highest dosage. Eli Lilly and Co's stock surged 14% in Pre-Market Trading, while Novo-Nordisk A/S's European shares fell nearly 6.8%.
Top Premarket Decliners
Intuit To Rally Around 19%? Here Are 10 Top Analyst Forecasts For Thursday